



Quest Diagnostics to Present at Investor Conference

October 8, 2001

TETERBORO, N.J., Oct 8, 2001 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that Kenneth W. Freeman, Chairman and Chief Executive Officer, is scheduled to speak at the UBS Warburg Global Life Sciences Conference on Tuesday, October 9, 2001 in New York City.

The Quest Diagnostics presentation is scheduled to begin at approximately 9:20 A.M. Eastern Time. The public is invited to listen to the live presentation by telephone by dialing 800-500-0177 in the U.S. and 719-457-2679 from outside the U.S. After the presentation, a recording will be available for up to four weeks and may be heard by dialing 800-759-8603 in the U.S. and 402-220-8537 from outside the U.S.

Quest Diagnostics will release financial results for the third quarter ended September 30, 2001, after the close of the stock market on October 18, 2001. The company is currently in a "quiet" period and will discuss results for the third quarter during a conference call on October 19 at 8:00 A.M. Eastern Time. To hear a simulcast of the call over the Internet, or a replay, registered analysts may access StreetEvents at: <http://www.streetevents.com> and all others may access the Quest Diagnostics website at: <http://www.questdiagnostics.com>. In addition, a replay of the call will also be available from 10 A.M. on October 19 through 5 P.M. on October 22 to investors in the U.S. by dialing 800-754-7906. Investors outside the U.S. may dial 402-220-0366. No password is required for either number.

Quest Diagnostics is the nation's leading provider of diagnostic testing, information and services with \$3.4 billion in annual revenues. The company's diagnostic testing yields information that enables health care professionals and consumers to make better decisions to improve health. Quest Diagnostics offers patients and physicians the broadest access to diagnostic testing services through its national network of approximately 30 full-service laboratories, 150 rapid response laboratories and more than 1,300 patient service centers, where specimens are collected. Quest Diagnostics is the leading provider of esoteric testing, including gene-based testing, and is the leader in routine medical testing, drugs of abuse testing, and non-hospital- based anatomic pathology testing. Through partnerships with pharmaceutical, biotechnology and information technology companies, Quest Diagnostics provides support to help speed the development of health care insights and new therapeutics. Additional company information can be found on the Internet at: <http://www.questdiagnostics.com>.

The statements in this press release which are not historical facts or information may be forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the outcome to be materially different. Certain of these risks and uncertainties are listed in the Quest Diagnostics Incorporated 2000 Form 10-K and subsequent filings.

MAKE YOUR OPINION COUNT - Click Here
<http://tbutton.prnewswire.com/prn/11690X52768510>

SOURCE Quest Diagnostics Incorporated

CONTACT: Investors - Cathy Doherty, +1-201-393-5030, or Media - Gary Samuels, +1-201-393-5700, both of Quest Diagnostics Incorporated

URL: <http://www.questdiagnostics.com>
<http://www.prnewswire.com>

Copyright (C) 2001 PR Newswire. All rights reserved.